Toko Hashimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toko Hashimoto has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Takao Koike
T. Koike, MD, PhD, Professor Emeritus of Hokkaido University, Japan, Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan
2 shared publications - Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
2 shared publications - Hideyuki Koide
Department of Medicine II, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
1 shared publication - Hiroshi Kataoka
Department of Medicine II, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
1 shared publication Nobuya Yoshida
Department of Medicine Ⅱ, Hokkaido University Graduate School of Medicine
1 shared publication- Shinsuke Yasuda
Department of Rheumatology, Institute of Science Tokyo , Tokyo
1 shared publication
Latest Publications
- Open Access
- 20 September 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (5) , R154
Aberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis
Introduction: An unidentified population of peripheral blood mononuclear cells (PBMCs) express Ras guanine nucleotide releasing protein 4 (RasGRP4). The aim of our study was to identify the cells in human blood that express hRasGRP4, and then to determine if hRasGRP4 was altered in any patient with rheumatoid arthritis (RA). Methods: Monocytes and T cells were purified from PBMCs of normal individuals, and were evaluated for their expression of RasGRP4 mRNA/protein. The levels of RasGRP4 transcripts were evaluated in the PBMCs from healthy volunteers and RA patients by real-time quantitative PCR. The nucleotide sequences of RasGRP4 cDNAs were also determined. RasGRP4 protein expression in PBMCs/monocytes was evaluated. Recombinant hRasGRP4 was expressed in mammalian cells. Results: Circulating CD14+ cells in normal individuals were found to express hRasGRP4. The levels of the hRasGRP4 transcript were significantly higher in the PBMCs of our RA patients relative to healthy individuals. Sequence analysis of hRasGRP4 cDNAs from these PBMCs revealed 10 novel splice variants. Aberrantly spliced hRasGRP4 transcripts were more frequent in the RA patients than in normal individuals. The presence of one of these abnormal splice variants was linked to RA. The levels of hRasGRP4 protein in PBMCs tended to be lower. As expected, the defective transcripts led to altered and/or nonfunctional protein in terms of P44/42 mitogen-activated protein (MAP) kinase activation. Conclusions: The identification of defective isoforms of hRasGRP4 transcripts in the PBMCs of RA patients raises the possibility that dysregulated expression of hRasGRP4 in developing monocytes plays a pathogenic role in a subset of RA patients.
- 20 September 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (5) , R154
Open AccessAberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis
Introduction: An unidentified population of peripheral blood mononuclear cells (PBMCs) express Ras guanine nucleotide releasing protein 4 (RasGRP4). The aim of our study was to identify the cells in human blood that express hRasGRP4, and then to determine if hRasGRP4 was altered in any patient with rheumatoid arthritis (RA). Methods: Monocytes and T cells were purified from PBMCs of normal individuals, and were evaluated for their expression of RasGRP4 mRNA/protein. The levels of RasGRP4 transcripts were evaluated in the PBMCs from healthy volunteers and RA patients by real-time quantitative PCR. The nucleotide sequences of RasGRP4 cDNAs were also determined. RasGRP4 protein expression in PBMCs/monocytes was evaluated. Recombinant hRasGRP4 was expressed in mammalian cells. Results: Circulating CD14+ cells in normal individuals were found to express hRasGRP4. The levels of the hRasGRP4 transcript were significantly higher in the PBMCs of our RA patients relative to healthy individuals. Sequence analysis of hRasGRP4 cDNAs from these PBMCs revealed 10 novel splice variants. Aberrantly spliced hRasGRP4 transcripts were more frequent in the RA patients than in normal individuals. The presence of one of these abnormal splice variants was linked to RA. The levels of hRasGRP4 protein in PBMCs tended to be lower. As expected, the defective transcripts led to altered and/or nonfunctional protein in terms of P44/42 mitogen-activated protein (MAP) kinase activation. Conclusions: The identification of defective isoforms of hRasGRP4 transcripts in the PBMCs of RA patients raises the possibility that dysregulated expression of hRasGRP4 in developing monocytes plays a pathogenic role in a subset of RA patients.
- 1 July 2007
- Vol. 65 (7) , 1251-8
[Infliximab].
A number of over-sea study showed the immediate and dramatic anti-inflammatory effects of infliximab(IFX) in patients with rheumatoid arthritis (RA). In addition, significant reduction of bone/joint destruction by IFX was proven in RA patients. On the other hand, some serious adverse effects of IFX were documented. In Japan, IFX was approved as a biological reagent against RA on 2003, and nationwide post marketing surveillance was conducted in the consecutive 5,000 RA patients on IFX. The data showed that 91.6% of patients had overall efficacy as "marked improvement" or "improvement". Serious adverse reaction was reported in 6.2%. Therefore, IFX is very effective and well tolerated in Japanese patients with RA.
- 1 July 2007
- Vol. 65 (7) , 1251-8
[Infliximab].
A number of over-sea study showed the immediate and dramatic anti-inflammatory effects of infliximab(IFX) in patients with rheumatoid arthritis (RA). In addition, significant reduction of bone/joint destruction by IFX was proven in RA patients. On the other hand, some serious adverse effects of IFX were documented. In Japan, IFX was approved as a biological reagent against RA on 2003, and nationwide post marketing surveillance was conducted in the consecutive 5,000 RA patients on IFX. The data showed that 91.6% of patients had overall efficacy as "marked improvement" or "improvement". Serious adverse reaction was reported in 6.2%. Therefore, IFX is very effective and well tolerated in Japanese patients with RA.